Kesatuan Eropah - Estonia - EMA (European Medicines Agency)

novartis europharm limited  - alpelisib - rinnanäärmed - antineoplastilised ained - piqray on näidustatud kombinatsioonis fulvestrant raviks postmenopausis naistele, meestele ja hormooni retseptori (hr)-positiivne, inimese epidermaalse kasvufaktori retseptor 2 (her2)-negatiivne, lokaalselt kaugelearenenud või metastaatilise rinnavähi koos pik3ca mutatsiooni pärast haiguse progresseerumise pärast sisesekretsioonisüsteemi ravi monotherapy (vt lõik 5.

Estonia - Estonia - Ravimiamet

zentiva k.s. - salmeterool+flutikasoon - annustatud inhalatsioonipulber - 50mcg+500mcg 1annus 60annus 1tk; 50mcg+500mcg 1annus 60annus 10tk; 50mcg+500mcg 1annus 60annus 2tk

Estonia - Estonia - Ravimiamet

zentiva k.s. - salmeterool+flutikasoon - annustatud inhalatsioonipulber - 50mcg+100mcg 1annus 60annus 1tk; 50mcg+100mcg 1annus 60annus 2tk; 50mcg+100mcg 1annus 60annus 10tk; 50mcg+100mcg 1annus 60annus 3tk

Estonia - Estonia - Ravimiamet

zentiva k.s. - salmeterool+flutikasoon - annustatud inhalatsioonipulber - 50mcg+250mcg 1annus 60annus 3tk; 50mcg+250mcg 1annus 60annus 1tk; 50mcg+250mcg 1annus 60annus 10tk

Kesatuan Eropah - Estonia - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - idecabtagene vicleucel - multiple myeloma; neoplasms; cancer; neoplasms, plasma cell; hemostatic disorders; vascular diseases; cardiovascular diseases; paraproteinemias; blood protein disorders; hematologic diseases; hemic and lymphatic diseases; hemorrhagic disorders; infectious mononucleosis; lymphoproliferative disorders; immunoproliferative disorders; immune system diseases - antineoplastilised ained - abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

Kesatuan Eropah - Estonia - EMA (European Medicines Agency)

janssen-cilag international n.v.    - amivantamab - kartsinoom, mitteväikerakk-kopsu - antineoplastilised ained - rybrevant as monotherapy is indicated for treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating epidermal growth factor receptor (egfr) exon 20 insertion mutations, after failure of platinum-based chemotherapy.

Estonia - Estonia - Ravimiamet

fresenius kabi polska sp. z o.o. - deksametasoon - süstelahus - 4mg 1ml 2ml 50tk; 4mg 1ml 1ml 10tk

Estonia - Estonia - Ravimiamet

ideal trade links uab - flutikasoon+aselastiin - ninasprei, suspensioon - 50mcg+137mcg 1mõõtannus 120mõõtannus 1tk

Kesatuan Eropah - Estonia - EMA (European Medicines Agency)

eigerbio europe limited - lonafarnib - progeria; laminopathies - muud alimentary seedetrakti ja ainevahetust tooted, - zokinvy is indicated for the treatment of patients 12 months of age and older with a genetically confirmed diagnosis of hutchinson-gilford progeria syndrome or a processing-deficient progeroid laminopathy associated with either a heterozygous lmna mutation with progerin-like protein accumulation or a homozygous or compound heterozygous zmpste24 mutation.

Kesatuan Eropah - Estonia - EMA (European Medicines Agency)

stada arzneimittel ag - budesonide, micronised - glomerulonephritis, iga - antidiarrheals, soole põletikuvastased / antiinfective ained - kinpeygo is indicated for the treatment of primary immunoglobulin a (iga) nephropathy (igan) in adults at risk of rapid disease progression with a urine protein-to-creatinine ratio (upcr) ≥1. 5 g/gram.